Emerging Markets Earnings Roundup: Sanofi, Teva (Part 7)
This article was originally published in PharmAsia News
Executive Summary
Sanofi shows solid growth in emerging markets in the fourth quarter, including an impressive 35.1% gain in China. Teva in transition offers scant detail on emerging markets, but hints larger deals possible in 2014.